Protagonist Therapeutics Inc PTGX

NAS: PTGX | ISIN: US74366E1029   30/04/2024
25,11 USD (-1,76%)
(-1,76%)   30/04/2024

12 mei 2023 · Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 · Persbericht

11 mei 2023 · Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference · Persbericht

11 mei 2023 · Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association · Persbericht

4 mei 2023 · Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

7 maart 2023 · Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis · Persbericht

21 december 2022 · Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2022 · Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit · Persbericht

16 november 2022 · Protagonist Therapeutics Reports Granting of Inducement Award · Persbericht

8 november 2022 · Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

3 november 2022 · Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting · Persbericht

2 november 2022 · Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer · Persbericht

20 september 2022 · Protagonist Therapeutics Reports Granting of Inducement Award · Persbericht

4 augustus 2022 · Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

19 juli 2022 · Protagonist Therapeutics Reports Granting of Inducement Award · Persbericht

1 juni 2022 · Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference · Persbericht

26 mei 2022 · Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022 · Persbericht

4 mei 2022 · Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

25 april 2022 · Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis · Persbericht

19 april 2022 · Protagonist Therapeutics Reports Granting of Inducement Awards · Persbericht

28 maart 2022 · Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer · Persbericht

Mijn selecties